Tags

Type your tag names separated by a space and hit enter

Allogeneic bone marrow transplantation following a busulfan-based conditioning regimen in young children with acute lymphoblastic leukemia: a Cooperative Study of the Société Française de Greffe de Moelle.
Bone Marrow Transplant. 1995 Oct; 16(4):521-7.BM

Abstract

A subgroup of children with ALL remains at high risk of relapse despite the administration of intensive chemotherapeutic protocols and may benefit from allogeneic BMT. The cytoreductive regimen used most often combines TBI with cyclophosphamide. Nevertheless, miscellaneous long-term sequelae have been consequent upon radiotherapy, especially in young children. This retrospective multicentric study analyzes the outcome of children with ALL under 4 years of age receiving an HLA-genoidentical BMT following a radiation-free preparative regimen. A busulfan-based regimen with cyclophosphamide or melphalan +/- etoposide +/- cytarabine was given to 21 children (median age: 28 months, range 6-48). Sixteen patients with initial poor prognostic factors were transplanted in first complete response (CR) and five patients in relapse or second CR. With a median follow-up of 47 months, the results show an overall 4-year DFS of 61.1%. Leukemic recurrence was observed in eight patients. The preparative regimen was well-tolerated and there were no transplant-related deaths. A busulfan-based BMT preparative regimen may be a therapeutic alternative to TBI-containing regimens in young children. Efforts are currently aimed at reducing the relapse rate in these children by optimizing the tumoricidal potential of chemotherapy and the graft-versus-leukemia effect of allogeneic BMT.

Authors+Show Affiliations

Hôpital d'Enfants, Nancy, France.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study

Language

eng

PubMed ID

8528167

Citation

von Bueltzingsloewen, A, et al. "Allogeneic Bone Marrow Transplantation Following a Busulfan-based Conditioning Regimen in Young Children With Acute Lymphoblastic Leukemia: a Cooperative Study of the Société Française De Greffe De Moelle." Bone Marrow Transplantation, vol. 16, no. 4, 1995, pp. 521-7.
von Bueltzingsloewen A, Esperou-Bourdeau H, Souillet G, et al. Allogeneic bone marrow transplantation following a busulfan-based conditioning regimen in young children with acute lymphoblastic leukemia: a Cooperative Study of the Société Française de Greffe de Moelle. Bone Marrow Transplant. 1995;16(4):521-7.
von Bueltzingsloewen, A., Esperou-Bourdeau, H., Souillet, G., Demeocq, F., Mechinaud-Lacroix, F., Michel, G., Sadoun, A., Bernaudin, F., Cornu, G., & Donadieu, J. (1995). Allogeneic bone marrow transplantation following a busulfan-based conditioning regimen in young children with acute lymphoblastic leukemia: a Cooperative Study of the Société Française de Greffe de Moelle. Bone Marrow Transplantation, 16(4), 521-7.
von Bueltzingsloewen A, et al. Allogeneic Bone Marrow Transplantation Following a Busulfan-based Conditioning Regimen in Young Children With Acute Lymphoblastic Leukemia: a Cooperative Study of the Société Française De Greffe De Moelle. Bone Marrow Transplant. 1995;16(4):521-7. PubMed PMID: 8528167.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Allogeneic bone marrow transplantation following a busulfan-based conditioning regimen in young children with acute lymphoblastic leukemia: a Cooperative Study of the Société Française de Greffe de Moelle. A1 - von Bueltzingsloewen,A, AU - Esperou-Bourdeau,H, AU - Souillet,G, AU - Demeocq,F, AU - Mechinaud-Lacroix,F, AU - Michel,G, AU - Sadoun,A, AU - Bernaudin,F, AU - Cornu,G, AU - Donadieu,J, PY - 1995/10/1/pubmed PY - 1995/10/1/medline PY - 1995/10/1/entrez SP - 521 EP - 7 JF - Bone marrow transplantation JO - Bone Marrow Transplant VL - 16 IS - 4 N2 - A subgroup of children with ALL remains at high risk of relapse despite the administration of intensive chemotherapeutic protocols and may benefit from allogeneic BMT. The cytoreductive regimen used most often combines TBI with cyclophosphamide. Nevertheless, miscellaneous long-term sequelae have been consequent upon radiotherapy, especially in young children. This retrospective multicentric study analyzes the outcome of children with ALL under 4 years of age receiving an HLA-genoidentical BMT following a radiation-free preparative regimen. A busulfan-based regimen with cyclophosphamide or melphalan +/- etoposide +/- cytarabine was given to 21 children (median age: 28 months, range 6-48). Sixteen patients with initial poor prognostic factors were transplanted in first complete response (CR) and five patients in relapse or second CR. With a median follow-up of 47 months, the results show an overall 4-year DFS of 61.1%. Leukemic recurrence was observed in eight patients. The preparative regimen was well-tolerated and there were no transplant-related deaths. A busulfan-based BMT preparative regimen may be a therapeutic alternative to TBI-containing regimens in young children. Efforts are currently aimed at reducing the relapse rate in these children by optimizing the tumoricidal potential of chemotherapy and the graft-versus-leukemia effect of allogeneic BMT. SN - 0268-3369 UR - https://www.unboundmedicine.com/medline/citation/8528167/Allogeneic_bone_marrow_transplantation_following_a_busulfan_based_conditioning_regimen_in_young_children_with_acute_lymphoblastic_leukemia:_a_Cooperative_Study_of_the_Société_Française_de_Greffe_de_Moelle_ L2 - https://ClinicalTrials.gov/search/term=8528167 [PUBMED-IDS] DB - PRIME DP - Unbound Medicine ER -